Q: We are using a biosimilar for infliximab but it is manufactured by Merck/Samsung rather than Pfizer/Hospira. CMS requires that a manufacturer specific modifier be appended to the HCPCS code. Is there a new one for Merck/Samsung?
At a recent meeting, the Medicare Payment Advisory Commission (MedPAC) discussed an alternative policy to replace the Merit-based Incentive Payment System (MIPS) in order to reduce provider burden. MedPAC is an organization which advises CMS on Medicare policy issues.
Cognitive computing will transform the future of clinical care as we know it in three direct ways: making data accessible, making it approachable, and making it actionable.
This week’s Medicare updates include corrections to the IPPS final rule; corrections to the Skilled Nursing Facilities Prospective Payment System final rule; year 3 baseline data on Medicare payments for clinical diagnostic laboratory tests; and more!
